Want to see DE:DMP full AI Analyst Report?
Top Page
Dermapharm Holding SE
(XETRA:DMP)
Select Model
Select Model
Rating:65Neutral
Price Target:
€43.00
▲(2.38% Upside)
Action:Reiterated
Date:08/27/26
The score is driven primarily by improving financial quality—stronger profitability and a materially de-risked balance sheet—partly offset by weakening free cash flow momentum. Technical signals remain soft (below key moving averages with negative MACD), while valuation is moderately supportive with a reasonable P/E and a ~2.2% dividend yield.
Positive Factors
Improved profitability and renewed growth
The return to revenue growth alongside higher net and EBIT margins indicates improving operating execution. If sustained, stronger profitability can support reinvestment, resilience against cost pressure, and earnings growth across Dermapharm’s branded and manufacturing businesses.
Negative Factors
Declining free cash flow momentum
Although cash generation remains positive, the decline in free cash flow and weaker conversion from earnings reduce financial flexibility. Persistent deterioration could limit investment capacity, slow deleveraging, and make reported profit growth less valuable to shareholders.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved profitability and renewed growth
The return to revenue growth alongside higher net and EBIT margins indicates improving operating execution. If sustained, stronger profitability can support reinvestment, resilience against cost pressure, and earnings growth across Dermapharm’s branded and manufacturing businesses.
Read all positive factors
Dermapharm Holding SE (DMP) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€1.93B
Dividend Yield2.24%
Average Volume (3M)46.66K
Price to Earnings (P/E)14.2
Beta (1Y)0.42
Revenue Growth0.39%
EPS Growth38.58%
CountryDE
Employees3,619
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)2.77
Shares Outstanding49,540,810
10 Day Avg. Volume32,627
30 Day Avg. Volume46,665
Financial Highlights & Ratios
PEG Ratio0.96
Price to Book (P/B)3.05
Price to Sales (P/S)1.82
P/FCF Ratio15.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€52.00Price Target Upside23.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)2.66
Revenue Forecast (FY)€1.20B
Dermapharm Holding SE Business Overview & Revenue Model
Company Description
Dermapharm Holding SE, alongside its group companies, specializes in the off-patent branded pharmaceutical market, serving both German and international clients. The company’s operations are organized into three primary divisions: Branded Pharmace...
How the Company Makes Money
Dermapharm makes money primarily by selling pharmaceutical and healthcare products and by providing manufacturing-related services. Key revenue streams include: (1) Branded pharmaceuticals (Rx and other drug products): Dermapharm generates revenue...
Dermapharm Holding SE Financial Statement Overview
Summary
Income Statement
73
Positive
Balance Sheet
76
Positive
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.18B | 1.16B | 1.18B | 1.14B | 1.02B | 942.91M |
| Gross Profit | 410.33M | 391.71M | 767.07M | 719.16M | 660.83M | 620.69M |
| EBITDA | 337.90M | 314.31M | 320.91M | 265.55M | 329.81M | 358.10M |
| Net Income | 146.54M | 132.41M | 113.79M | 62.37M | 134.24M | 209.58M |
Balance Sheet | ||||||
| Total Assets | 2.24B | 2.20B | 2.08B | 2.16B | 1.41B | 1.41B |
| Cash, Cash Equivalents and Short-Term Investments | 195.56M | 203.41M | 121.71M | 159.54M | 161.36M | 172.06M |
| Total Debt | 1.17B | 1.05B | 979.61M | 1.08B | 516.45M | 580.30M |
| Total Liabilities | 1.71B | 1.50B | 1.47B | 1.62B | 880.34M | 907.13M |
| Stockholders Equity | 536.71M | 694.38M | 604.42M | 539.21M | 531.59M | 497.32M |
Cash Flow | ||||||
| Free Cash Flow | 171.43M | 139.39M | 163.14M | 177.88M | 249.52M | 189.16M |
| Operating Cash Flow | 219.81M | 181.51M | 201.38M | 219.42M | 288.53M | 250.37M |
| Investing Cash Flow | -106.65M | -110.03M | -29.61M | -415.43M | -99.01M | -129.35M |
| Financing Cash Flow | -81.06M | 13.32M | -209.17M | 204.54M | -199.77M | -80.98M |
Dermapharm Holding SE Technical Analysis
Positive
42.00
Price Trends
39.83
Negative
43.19
Negative
41.37
Negative
Market Momentum
-0.23
Negative
50.35
Neutral
69.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:DMP, the sentiment is Positive. The current price of 42 is above the 20-day moving average (MA) of 38.77, above the 50-day MA of 39.83, and above the 200-day MA of 41.37, indicating a neutral trend. The MACD of -0.23 indicates Negative momentum. The RSI at 50.35 is Neutral, neither overbought nor oversold. The STOCH value of 69.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:DMP.
Dermapharm Holding SE Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | €1.93B | 14.21 | 22.38% | 2.24% | 0.39% | 38.58% | |
63 Neutral | €58.70B | 25.40 | 8.08% | 1.59% | -0.40% | -17.22% | |
55 Neutral | €280.56M | 24.91 | 2.16% | ― | 9.88% | -38.44% | |
54 Neutral | €342.50M | -13.34 | -6.41% | ― | 18.28% | 85.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | €21.15M | -1.88 | -127.78% | ― | 27.97% | -1432.58% |
* Healthcare Sector Average
DE:DMP
Dermapharm Holding SE
39.05
7.10
22.23%
DE:B8FK
Biofrontera
3.50
0.79
29.15%
DE:MRK
Merck KGaA
137.40
30.10
28.05%
DE:ILM1
Medios AG
10.88
-2.56
-19.05%
DE:PHH2
PAUL HARTMANN AG
198.50
-16.80
-7.80%
DE:FYB
Formycon AG
19.12
-3.38
-15.02%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.